Consistent with the evidence in vitro, mouse models have shown that PPARγ ligands reduce the growth of tumors originated from subcutaneously injected human CRC cells and the number of aberrant crypt foci (ACF) in a chemically induced model of IBD [60, 69]. This evidence concerns the gene PPARG and colorectal carcinoma.